Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Begins Phase I Testing of Cancer Drug

Premium

Dicerna Pharmaceuticals this week announced that it has begun dosing patients in a Phase I trial of its RNAi cancer treatment DCR-MYC, formerly known as DCR-M1711.

In the dose-escalating trial, once-weekly infusions of the drug will be administered to up to 66 patients with solid tumors, multiple myeloma, or lymphoma who are refractory or unresponsive to other treatments for three weeks.

Endpoints of the trial include determination of the drug's maximum tolerated dose, as well as its pharmacokinetics, pharmacodynamics, and potential antitumor activity. Data is expected to be available next year.

Dicerna's CSO Bob Brown recently stated that this study will be followed by another Phase I trial in advanced hepatocellular carcinoma patients.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.